What is BPC-157?
BPC-157, or Body Protection Compound 157, is a synthetic pentadecapeptide — a chain of 15 amino acids — derived from a protective protein found naturally in human gastric juice. It was first isolated and studied in the 1990s by researchers investigating the stomach's remarkable ability to resist damage and heal rapidly despite its hostile acidic environment.
Since then, BPC-157 has become one of the most extensively studied peptides in preclinical research, with hundreds of animal studies documenting its effects across virtually every tissue type — tendons, ligaments, muscles, bone, gut lining, brain, and cardiovascular tissue. All published research to date has been conducted in animal models; no completed phase II or III human clinical trials exist as of 2026, though the safety and tolerability data from animal studies is exceptionally clean.
Research on BPC-157 is indexed extensively on PubMed, where over 150 peer-reviewed studies document its mechanisms. The NIH National Center for Biotechnology Information catalogs much of this research through its PMC database.
Context: All BPC-157 research is preclinical (animal models) as of 2026. The biohacking community uses it based on this extensive preclinical evidence and favorable observational reports. This article covers research-based protocols — not personal medical advice. Consult a qualified healthcare provider before starting any peptide protocol.
BPC-157 Dosing Guide
Standard research doses in the literature range from 1–10 mcg/kg/day in animal studies. Extrapolated to human use, this translates to approximately 250–500 mcg per day for most adults, with some protocols using up to 750 mcg in divided doses for acute injury applications.
Standard dosing ranges
- Conservative dose: 200–250 mcg/day — suitable for gut health protocols and first-time users
- Standard dose: 250–500 mcg/day — most common in the biohacking community for systemic repair
- Higher dose: 500–750 mcg/day (divided) — used for acute injury protocols, not for routine use
Dosing is typically once daily, though some practitioners split higher doses into morning and evening administrations. There is no established half-life data for humans; animal pharmacokinetics suggest a relatively short active window of several hours.
Injection vs Oral: Which is Right for You?
BPC-157 is available in two primary forms: injectable (subcutaneous or intramuscular) and oral capsules. The right choice depends on your primary target — systemic tissue repair versus localized gut healing.
Injectable BPC-157 (SubQ or IM)
Injectable administration delivers BPC-157 directly into circulation, providing systemic distribution to joints, tendons, muscles, and connective tissue throughout the body. This is the preferred route for:
- Joint injuries, tendon tears, or ligament damage
- Muscle repair and recovery acceleration
- Systemic anti-inflammatory effects
- Neurological or cardiovascular applications studied in research
Subcutaneous injections are standard — administered into the abdomen or near the injury site. Intramuscular delivery is used less frequently. Injectable BPC-157 is typically the lyophilized (freeze-dried) powder form requiring reconstitution with bacteriostatic water. Research on systemic BPC-157 mechanisms is documented on the NIH and searchable via PubMed.
Oral BPC-157
Oral BPC-157 is typically formulated as BPC-157 arginate salt, which is more stable in the GI environment than the standard form. Bioavailability for systemic effects is lower than injectable; however, for gut-specific targets — leaky gut, IBD, gastric ulcers, GERD, and intestinal repair — oral delivery is actually preferable, as it directly contacts the mucosal tissue it is intended to heal.
- Gut healing (oral): 250–500 mcg/day, taken on an empty stomach
- Systemic effects (oral): 500 mcg–1 mg/day to compensate for lower bioavailability
Bottom line: Injectable for joints, tendons, and systemic repair. Oral for gut lining, leaky gut, and GI conditions. Many experienced users run both simultaneously — standard injectable dose for systemic healing plus oral capsules for concurrent gut support.
BPC-157 Cycling Schedule
Unlike hormonal compounds that require post-cycle therapy or carry receptor downregulation risk, BPC-157 has not demonstrated tolerance development in research across multiple animal studies and extended dosing periods. Despite this, most practitioners use cycled protocols as a conservative default.
Standard cycling protocol
- Cycle length: 4–6 weeks on, 2–4 weeks off (conservative)
- Moderate protocol: 8–12 weeks on, 4 weeks off
- Continuous low-dose: Some practitioners run 200–250 mcg/day continuously for chronic gut conditions or long-term anti-inflammatory support
For acute injuries, some users front-load at the higher end of dosing (500 mcg/day) for the first 2–3 weeks, then taper to 250 mcg/day for the remainder of the cycle. Cycle length decisions should be informed by the target indication — acute injury cycles often run 4–6 weeks; preventive or chronic protocols may extend to 12 weeks.
Stacking BPC-157 with TB-500
The BPC-157 + TB-500 stack is the most popular combination in the biohacking and sports medicine community, and for good reason — the two peptides operate through fundamentally different and complementary mechanisms that together address recovery more completely than either compound alone.
How they work together
- BPC-157 drives localized tissue repair — it promotes angiogenesis (new blood vessel formation) at injury sites, upregulates growth factor receptors, and accelerates tendon-to-bone healing through nitric oxide pathway activation. Think of it as the targeted repair signal.
- TB-500 (Thymosin Beta-4) provides systemic healing and inflammation reduction — it sequesters actin, promotes cell migration, reduces acute and chronic inflammation, and supports systemic regeneration independent of specific injury location. Think of it as the body-wide recovery signal.
Their mechanisms are non-redundant. BPC-157 works locally through angiogenesis and growth factor modulation; TB-500 works systemically through actin regulation and satellite cell recruitment. Running both simultaneously addresses both the local repair process and the systemic inflammatory environment that otherwise slows it.
TB-500 research is cataloged at PubMed (thymosin beta-4), where studies document its actin-sequestering mechanism and systemic tissue repair effects.
BPC-157 + TB-500 protocol
| Compound | Dose | Frequency | Route | Cycle |
|---|---|---|---|---|
| BPC-157 | 250–500 mcg | Daily | SubQ injection | 8–10 weeks on, 4 off |
| TB-500 | 2–2.5 mg | 2× per week | SubQ injection | 8–10 weeks on, 4 off |
Run both compounds on the same cycle timeline. Most practitioners inject BPC-157 daily in the morning and TB-500 twice weekly on non-consecutive days (e.g., Monday and Thursday). No PCT is required. For the complete stack protocol — loading vs maintenance phases, injection scheduling, and what results to expect — see the TB-500 + BPC-157 stack guide.
Reconstitution and Storage
BPC-157 is supplied as a lyophilized (freeze-dried) powder in sealed vials, typically 5 mg per vial. Proper reconstitution and storage are critical to maintaining peptide integrity.
Reconstitution steps
- Using a fresh alcohol swab, clean the top of both the BPC-157 vial and the bacteriostatic water vial
- Draw the desired volume of bacteriostatic water into a syringe (typically 1–2 mL per 5 mg vial)
- Inject the water slowly along the wall of the BPC-157 vial — do not inject directly onto the powder
- Gently swirl (never shake) until the powder fully dissolves into a clear solution
- Transfer to refrigeration immediately after reconstitution
Concentration and dose calculation
Adding 2 mL of bacteriostatic water to a 5 mg vial gives a concentration of 2,500 mcg/mL. A 250 mcg dose requires 0.1 mL (10 units on an insulin syringe). Adding 1 mL gives 5,000 mcg/mL — a 250 mcg dose is then 0.05 mL (5 units). Use a peptide dose calculator to compute your exact draw volume for any concentration.
Storage
- Lyophilized (unreconstituted): Room temperature for shipping and short-term storage; refrigerate or freeze for long-term storage
- Reconstituted: Refrigerate at 2–8°C (standard refrigerator), use within 30 days
- Do not freeze reconstituted peptide — this degrades the solution
- Protect from light; keep vials in the box or a dark container
Track Your BPC-157 Protocol with BioStackIQ
A BPC-157 cycle involves daily injections, cycle start and end dates, dose adjustments, and often a concurrent TB-500 protocol on a different schedule. Tracking all of this in a notes app is workable for a single cycle; it breaks down when you are managing multiple compounds, comparing responses across cycles, or trying to correlate biomarker results with protocol timing.
BioStackIQ's protocol builder lets you add BPC-157 and TB-500 as separate compounds, set individual doses and frequencies, log each injection, and track how your body responds across the full cycle timeline. When you adjust a dose or add a compound mid-cycle, the dashboard captures that change in context — so your retrospective data is clean and usable.
- Build your BPC-157 protocol → — free, takes under 5 minutes
- Rate My Stack — get an AI-generated safety and synergy score for your current protocol before you start